Functional studies on the anti-pathoangiogenic properties of CM101

Angiogenesis

Volumn 2, Issue 3, 1998, Pages 219-233

  Yan, He Ping ^a   Carter, Clint E ^a   Wang, En Ze ^a   Page, David L ^a   Washington, Kay ^a   Wamil, Barbara D ^a   Yakes, F Michael ^a   Thurman, Gary B ^a   Hellerqvist, Carl G ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Anti tumor action; Complement; Cytokines; Endothelial cells; Immunohistochemistry; Polysaccharide; RT PCR

Indexed keywords

STREPTOCOCCUS SP. 'GROUP B';

EID: 0001090653     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009258801899     Document Type: Article

References (25)

1. Hellerqvist CG, RoJas J, Green RS, et al. Studies on group B β-hemolytic streptococcus. I. Isolation and partial characterization of an extracellular toxin. Pediatr Res 1981; 15, 892-898.
2. Rojas J, Green RS, Hellerqvist CG, et al. Studies on group B β-hemolytic streptococcus. II. Effects on pulmonary hemo-dynamics and vascular permeability in unanesthetized sheep. Pediatr Res 1981; 15, 899-904.
3. Sandberg K, Edberg KE, Fish W, et al. Thromboxane receptor blockage (SQ 29548) in group B streptococcal (GBS) toxin challenge in young lambs. Pediatr Res 1994; 35, 571-579.
4. Rojas J, Larrson LE, Hellerqvist CG, et al. Pulmonary hemodynamic and ultrastructural changes associated with group B β-hemolytic streptococcal toxemia in adult sheep and newborn lambs. Pediatr Res 1983; 17, 1002-1008.
5. Hellerqvist CG. Therapeutic agent and method of inhibiting vascularization of tumors. US Patent 5,010,062, April 23, 1991.
6. Sundell HW, Yan H-P, Wu K, et al. Isolation and identification of group B beta-hemolytic streptococcal (GBS) toxin from septic newborn infants. Pediatr Res 1997; 39, 302A.
7. Hellerqvist CG, Thurman GB, Page DL, et al. Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B β-hemolytic streptococcus. J Cancer Res Clin Oncol 1993; 120, 63-70.
8. Thurman GB, Russell BA, York GE, et al. Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors. J Cancer Res Clin Oncol 1994; 120, 479-484.
9. Hellerqvist CG, Thurman GB, Russell BA, et al. Anti-tumor effects of GBS toxin are caused by induction of a targeted inflammatory reaction. In: Maragoudakis ME, Gullino PM, Lelkes PI, eds. NATO/ASI Series - Angiogenesis: Molecular Biology, Clinical Aspects, Series A: Life Sciences. New York: Plenum 1993; 263, 265-269.
10. Thurman GB, Page DL, Wamil BD, et al. Acute inflammatory changes in subcutaneous microtumors in mice ears induced by intravenous CM101 (GBS toxin). J Cancer Res Clin Oncol 1996; 122, 549-553.
11. DeVore RF, Hellerqvist CG, Wakefield GB, et al. A phase I study of the antineovascularization drug CM101. J Clin Cancer Res 1997; 3, 365-372.
12. Wamil BD, Thurman GB, DeVore RF, et al. Soluble e-Selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol 1997; 123, 173-179.
13. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996; 98, 50-61.
14. Hellerqvist CG, Lloyd S, Wang E, et al. Modulation of interleukin-12 mRNA expression in leukocytes of cancer patients treated with CM101. Ann NY Acad Sci 1995; 795, 346-348.
15. Fu C, Carter CE. Detection of circulating antigen in human schistosomiasis japonica using monoclonal antibody. Am J Trop Med Hyg 1990; 42, 347-351.
16. Oncor. In Situ Apoptosis Detection 1994.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning - A Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 1989: 10.51-10.69.
18. Liszewki KM, Atkinson JP. The complement system. In: Paul WE, ed. Fundamental Immunology, New York: Raven Press, 1993: 917-939.
19. Ochs HD, Nonoyama S, Zhu Q, et al. Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol Immunopathol 1993; 67, 33-40.
20. Ward PA. Role of complement, chemokines and regulatory cytokines in acute lung injury (Review). Ann NY Acad Sci 1996; 796, 104-112.
21. Parkinson DR. Present status of biological response modifiers in cancer. Am J Med 1995; 99, 545.
22. Donato NJ and Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and -21 WAF1 proteolysis in ME-180 cells. J Biol Chem 1998; 273, 5067-5072.
23. Hellerqvist CG, Wang E, Wamil BD, et al. Evidence of induced apoptosis in cancer patients treated with CM101. Proc Am Soc Clin Oncol 1997; 16, 546a.
24. Hellerqvist CG, Yan HP, Carter CE, et al. Identification of GBS toxin in neonatal fluids from group B streptococcus (GBS) infected neonates. Proc Am Soc Microbiol 1996; B-348, 215.
25. Hellerqvist CG, Yan HP, Carter CE, et al. CM101 induces a complement-activated inflammatory response targeting tumor neovasculature. Proc Am Ass Cancer Res 1996; 73, 487 (abstr 3328).